1[1]Valerie B, Emily B, G illian R. Evidence from randomised trials on the longterm effects of hormone replacement therapy. Lancet,2002,360: 942-944.
2[2]Troisi RJ, Cowie CC, Harris M. Hormone replacement therapy and glucose metabolism. Obstet Gynecol,2000,96:665-670.
3[3]Ferera M,Petrie JR,Hillier C,et al. Hormone replacement therapy can argument vascular relaxation in postmenopausal women with type 2 diabetes.Hum Reprod,2002,23:1731-1736.
4[4]Grodstein F, Stampfer MJ, Falkeborn M, et al. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology, 1999,10(5) :476-280.
5[5]Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA, 1998,280: 321-333.
6[6]Viscoli CM, Brass LM, Keman WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl Med, 2001,345: 1243-1249.
7[7]Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA, 2001,285: 2891-2897.
8[8]Cauley TA, Black DM, Barrett-connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/progestin Replacement study(HERS). Am J Med,2001,110:442-450.
9[9]Hulley S, Furberg C, Barrett-Connor E. Heart and Estrogen/progestin Replacement Study Follow-up( HERS Ⅱ ): Noncardiovascular disease outcomes during 6.8 years or hormone therapy. JAMA,2002,288:58-66.
10[10]Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 1998,280:605-613.
